Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy
Open accessAbstract
Deciphering how TCR signals are modulated by coinhibitory receptors is of fundamental and clinical interest. Using quantitative interactomics, we define the composition and dynamics of the PD-1 and BTLA coinhibitory signalosomes in primary effector T cells and at the T cell-antigen-presenting cell interface. We also solve the existing controversy regarding the role of the SHP-1 and SHP-2 protein-tyrosine phosphatases in mediating PD-1 coinhibition. PD-1 predominantly recruits SHP-2, but when absent, it recruits SHP-1 and remains functional. In contrast, BTLA predominantly recruits SHP-1 and to a lesser extent SHP-2. By separately analyzing the PD-1-SHP-1 and PD-1-SHP-2 complexes, we show that both dampen the TCR and CD28 signaling pathways equally. Therefore, our study illustrates how comparison of coinhibitory receptor signaling via quantitative interactomics in primary T cells unveils their extent of redundancy and provides a rationale for designing combinations of blocking antibodies in cancer immunotherapy on the basis of undisputed modes of action.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mass spectrometry of PD-1 signalosome assembly in primary effector T cells confirmed that PD-1 mainly recruited SHP2.
“Previous studies showed quantitatively applied mass spectrometry of PD‐1 signalosome assembly in primary effector T cells and confirmed that PD‐1 mainly recruited SHP2 [282, 287, 288].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [282]
BTLA recruits SHP1 to abrogate CD28 and TCR signaling, whereas PD-1 recruits SHP2.
“BTLA compels the strongest phosphatase SHP1 to abrogate the CD28 and TCR signaling mechanisms. In contrast, PD‐1 signaling recruits the weakened phosphatase SHP2 [282].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [282]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 1× · see citing works
“as the interaction stoichiometry) by intensity-based absolute quantification (iBAQ; Schwanhäusser et al., 2011) and the estimated values were normalized to the bait (Figure 1I, iBAQ column; Table S3).”
MethodIshida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259 · see citing works
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087 · see citing works
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070 · see citing works
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.108 · Cited by 1,980 · see citing works
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · see citing works
The CRAPome: a contaminant repository for affinity purification–mass spectrometry data
Mellacheruvu, D., Wright, Z., Couzens, A. L., Lambert, J.-P., St-Denis, N. A., Li, T., Miteva, Y. V., Hauri, S., Sardiu, M. E., Low, T. Y., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2557 · Cited by 1,686 · see citing works
Self-citationSiddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679 · see citing works
A Human Interactome in Three Quantitative Dimensions Organized by Stoichiometries and Abundances
Hein, M. Y., Hubner, N. C., Poser, I., Cox, J., Nagaraj, N., Toyoda, Y., Gak, I. A., Weisswange, I., Mansfeld, J., Buchholz, F., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.053 · Cited by 1,270 · see citing works
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · see citing works
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925 · see citing works
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · see citing works
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791 · see citing works
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778 · see citing works
Soriano, P. M. (1997) · Development · doi:10.1242/dev.124.14.2691 · Cited by 709 · see citing works
CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043208 · Cited by 659 · see citing works
T cell receptor ligation induces the formation of dynamically regulated signaling assemblies
Bunnell, S. C., Hong, D. I., Kardon, J. R., Yamazaki, T., McGlade, C. J., Barr, V. A., & Samelson, L. E. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200203043 · Cited by 633 · see citing works
Using i RT , a normalized retention time for more targeted measurement of peptides
Escher, C., Reiter, L., MacLean, B., Ossola, R., Herzog, F., Chilton, J. M., MacCoss, M. J., & Rinner, O. (2012) · PROTEOMICS · doi:10.1002/pmic.201100463 · Cited by 586 · see citing works
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways
Štefanová, I., Hemmer, B., Vergelli, M., Martin, R., Biddison, W. E., & Germain, R. N. (2003) · Nature Immunology · doi:10.1038/ni895 · Cited by 465 · see citing works
Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
Odorizzi, P. M., Pauken, K. E., Paley, M., Sharpe, A. H., & Wherry, E. J. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20142237 · Cited by 464 · see citing works
Ahrends, T., Spanjaard, A., Pilzecker, B., Bąbała, N., Bovens, A. A., Xiao, Y., Jacobs, H., & Borst, J. G. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.009 · Cited by 416 · see citing works
Direct Regulation of ZAP-70 by SHP-1 in T Cell Antigen Receptor Signaling
Plas, D. R., Johnson, R. R., Pingel, J. T., Matthews, R. J., Dalton, M., Roy, G., Chan, A. C., & Thomas, M. L. (1996) · Science · doi:10.1126/science.272.5265.1173 · Cited by 392 · see citing works
Sugiura, D., Maruhashi, T., Okazaki, I.-M., Shimizu, K., Maeda, T. K., Takemoto, T., & Okazaki, T. (2019) · Science · doi:10.1126/science.aav7062 · Cited by 386 · see citing works
Agouti C57BL/6N embryonic stem cells for mouse genetic resources
Pettitt, S. J., Liang, Q., Rairdan, X. Y., Moran, J. L., Prosser, H. M., Beier, D. R., Lloyd, K. C. K., Bradley, A., & Skarnes, W. C. (2009) · Nature Methods · doi:10.1038/nmeth.1342 · Cited by 384 · see citing works
Social network architecture of human immune cells unveiled by quantitative proteomics
Rieckmann, J. C., Geiger, R., Hornburg, D., Wolf, T., Kveler, K., Jarrossay, D., Sallusto, F., Shen-Orr, S. S., Lanzavecchia, A., Mann, M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3693 · Cited by 376 · see citing works
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372 · see citing works
Strength of PD-1 signaling differentially affects T-cell effector functions
Wei, F., Zhong, S., Ma, Z., Kong, H., Medvec, A. R., Ahmed, R., Freeman, G. J., Krogsgaard, M., & Riley, J. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305394110 · Cited by 306 · see citing works
FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells
Meng, X., Liu, X., Guo, X., Jiang, S., Chen, T., Hu, Z., Liu, H., Bai, Y., Xue, M., Hu, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0756-0 · Cited by 303 · see citing works
Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295 · see citing works
The cytotoxic T cell proteome and its shaping by the kinase mTOR
Hukelmann, J. L., Anderson, K. E., Sinclair, L. V., Grzes, K. M., Murillo, A. B., Hawkins, P. T., Stephens, L. R., Lamond, A. I., & Cantrell, D. A. (2016) · Nature Immunology · doi:10.1038/ni.3314 · Cited by 249 · see citing works
A DNA-Based T Cell Receptor Reveals a Role for Receptor Clustering in Ligand Discrimination
Taylor, M. J., Husain, K. B., Gartner, Z. J., Mayor, S., & Vale, R. D. (2017) · Cell · doi:10.1016/j.cell.2017.03.006 · Cited by 192 · see citing works
Gavrieli, M., Watanabe, N., Loftin, S. K., Murphy, T. L., & MURPHY, K. M. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.070 · Cited by 190 · see citing works
Zhao, Y., Harrison, D. L., Song, Y., Ji, J., Huang, J., & Hui, E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.054 · Cited by 185 · see citing works
Baitsch, L., Legat, A., Barba, L., Marraco, S. A. F., Rivals, J., Baumgaertner, P., Christiansen-Jucht, C., Bouzourène, H., Rimoldi, D., Pircher, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030852 · Cited by 184 · see citing works
PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation
Mizuno, R., Sugiura, D., Shimizu, K., Maruhashi, T., Watada, M., Okazaki, I., & Okazaki, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00630 · Cited by 170 · see citing works
Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo
Rota, G., Niogret, C., Dang, A. T., Barros, C. R., Fonta, N. P., Alfei, F., Morgado, L., Zehn, D., Birchmeier, W., Vivier, E., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.026 · Cited by 155 · see citing works
Teo, G., Kim, S., Tsou, C., Collins, B. C., Gingras, A., Nesvizhskii, A. I., & Choi, H. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.09.013 · Cited by 145 · see citing works
B and T lymphocyte attenuator regulates CD8+ T cell–intrinsic homeostasis and memory cell generation
Krieg, C., Boyman, O., Fu, Y., & Kaye, J. G. (2007) · Nature Immunology · doi:10.1038/ni1418 · Cited by 138 · see citing works
Roncagalli, R., Hauri, S., FIORE, F., Liang, Y., Chen, Z. J., Sansoni, A., Kanduri, K., Joly, R., Malzac, A., Lähdesmäki, H. J., et al. (2014) · Nature Immunology · doi:10.1038/ni.2843 · Cited by 131 · see citing works
Self-citationJunttila, M. R., Saarinen, S., Schmidt, T. G. M., Kast, J., & Westermarck, J. K. (2005) · PROTEOMICS · doi:10.1002/pmic.200400991 · Cited by 122 · see citing works
A THEMIS:SHP1 complex promotes T‐cell survival
Paster, W., Bruger, A. M., Katsch, K., Grégoire, C., Roncagalli, R., Fu, G., Gascoigne, N. R. J., Nika, K., Cohnen, A., Feller, S. M., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201387725 · Cited by 102 · see citing works
Self-citationIn vitro reconstitution of T cell receptor-mediated segregation of the CD45 phosphatase
Carbone, C. B., Kern, N., Fernandes, R. A., Hui, E., Su, X., García, K. C., & Vale, R. D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710358114 · Cited by 93 · see citing works
Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor
Peled, M., Tocheva, A. S., Sandigursky, S., Nayak, S., Philips, E. A., Nichols, K. E., Strazza, M., Azoulay-Alfaguter, I., Askenazi, M., Neel, B. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710437115 · Cited by 87 · see citing works
Tian, R., Wang, H., Gish, G. D., Petsalaki, E., Pasculescu, A., Shi, Y., Mollenauer, M. N., Bagshaw, R. D., Yosef, N., Hunter, T. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503286112 · Cited by 76 · see citing works
Stecher, C., Battin, C., Leitner, J. M., Zettl, M., Grabmeier‐Pfistershammer, K., Höeller, C., Zlabinger, G. J., & Steinberger, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00572 · Cited by 72 · see citing works
Rosenberger, G., Ludwig, C., Röst, H. L., Aebersold, R. H., & Malmström, L. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu200 · Cited by 60 · see citing works
Self-citationEnhanced differential expression statistics for data-independent acquisition proteomics
Suomi, T., & Elo, L. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-05949-y · Cited by 59 · see citing works
SOCS-6 Negatively Regulates T Cell Activation through Targeting p56 to Proteasomal Degradation
Choi, Y. B., Son, M., Park, M., Shin, J., & Yun, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073726 · Cited by 37 · see citing works
Precise Temporal Profiling of Signaling Complexes in Primary Cells Using SWATH Mass Spectrometry
Caron, É., Roncagalli, R., Hase, T., Wolski, W., Choi, M., Menoita, M. G., Durand, S., García‐Blesa, A., Fierro-Monti, I., Sajic, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.019 · Cited by 36 · see citing works
Self-citationGoyette, J., Salas, C. S., Coker-Gordon, N., Bridge, M., Isaacson, S. A., Allard, J. F., & Dushek, O. (2017) · Science Advances · doi:10.1126/sciadv.1601692 · Cited by 30 · see citing works
Bray, C., Wright, D. J., Haupt, S., Thomas, S., Stauss, H. J., & Zamoyska, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02595 · Cited by 27 · see citing works
Colquhoun, D. R., Lyashkov, A. E., Ubaida‐Mohien, C., Aquino, V. N., Bullock, B. T., Dinglasan, R. R., Agnew, B. J., & Graham, D. R. M. (2015) · PROTEOMICS · doi:10.1002/pmic.201500063 · Cited by 26 · see citing works
Li, K., Cheng, X., Tilevik, A., Davis, S. J., & Zhu, C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.763888 · Cited by 22 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,384 · see citing works
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 717 · see citing works
Patsoukis, N., Wang, Q., Strauss, L., & Boussiotis, V. A. (2020) · Science Advances · doi:10.1126/sciadv.abd2712 · Cited by 539 · see citing works
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323 · see citing works
T follicular helper cells in germinal center B cell selection and lymphomagenesis
Mintz, M. A., & Cyster, J. G. (2020) · Immunological Reviews · doi:10.1111/imr.12860 · Cited by 206 · see citing works
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 196 · see citing works
Targeting SHP2 as a promising strategy for cancer immunotherapy
Liu, Q., Qu, J., Zhao, M., Xu, Q., & Sun, Y. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104595 · Cited by 177 · see citing works
Interaction of SHP‐2 SH2 domains with PD‐1 ITSM induces PD‐1 dimerization and SHP‐2 activation
Patsoukis, N., Duke-Cohan, J. S., Chaudhri, A., Aksoylar, H.-I., Wang, Q., Council, A., Berg, A., Freeman, G. J., & Boussiotis, V. A. (2020) · Communications Biology · doi:10.1038/s42003-020-0845-0 · Cited by 169 · see citing works
Roles of BTLA in Immunity and Immune Disorders
Ning, Z., Liu, K., & Xiong, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654960 · Cited by 157 · see citing works
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Gaikwad, S. R., Agrawal, M. Y., Kaushik, I., Ramachandran, S., & Srivastava, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.014 · Cited by 153 · see citing works
PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity
Wiede, F., Lu, K., Du, X., Zeissig, M. N., Xu, R., Goh, P. K., Xirouchaki, C. E., Hogarth, S. J., Greatorex, S., Sek, K., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0694 · Cited by 140 · see citing works
Novel targets for immune-checkpoint inhibition in cancer
Borgeaud, M., Sandoval, J. L., Obéid, M., Banna, G. L., Michielin, O. A., Addeo, A., & Friedlaender, A. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102614 · Cited by 147 · see citing works
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders
Stanford, S. M., & Bottini, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00618-w · Cited by 136 · see citing works
PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
Xu, X., Hou, B., Fulzele, A., Masubuchi, T., Zhao, Y., Wu, Z., Hu, Y., Jiang, Y., Ma, Y., Wang, H., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201905085 · Cited by 131 · see citing works
Chen, S.-H., Dominik, P. K., Stanfield, J., Ding, S., Yang, W., Kurd, N. S., Llewellyn, R. A., Heyen, J. R. R., Wang, C., Melton, Z., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003464 · Cited by 131 · see citing works
Kerr, D. L., Haderk, F., & Bivona, T. G. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.11.007 · Cited by 124 · see citing works
Song, Y., Zhao, M., Zhang, H., & Yu, B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107966 · Cited by 125 · see citing works
Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression
McBride, M. A., Patil, T. K., Bohannon, J. K., Hernandez, A., Sherwood, E. R., & Patil, N. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624272 · Cited by 123 · see citing works
A comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119 · see citing works
Quantitative interactomics in primary T cells unveils TCR signal diversification extent and dynamics
Voisinne, G., Kersse, K., Chaoui, K., Lu, L., Chaix, J., Zhang, L., Menoita, M. G., Girard, L., Ounoughene, Y., Wang, H., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0489-8 · Cited by 101 · see citing works
Self-citationQuintana, E., Schulze, C. J., Myers, D. R., Choy, T. J., Mordec, K., Wildes, D. P., Shifrin, N. T., Belwafa, A., Koltun, E. S., Gill, A. L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3038 · Cited by 98 · see citing works
A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
Liang, S., Tran, E., Du, X., Dong, J., Sudholz, H., Chen, H., Qu, Z., Huntington, N. D., Babon, J. J., Kershaw, N. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40170-8 · Cited by 96 · see citing works
SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
Christofides, A., Katopodi, X.-L., Cao, C., Karagkouni, D., Aliazis, K., Yenyuwadee, S., Aksoylar, H., Pal, R., Mahmoud, M. A. A., Strauss, L., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01385-x · Cited by 95 · see citing works
Fang, T., Alvelid, J., Spratt, J., Ambrosetti, E., Testa, I., & Teixeira, A. I. (2021) · ACS Nano · doi:10.1021/acsnano.0c10632 · Cited by 90 · see citing works
Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors
Curnock, A. P., Bossi, G., Kumaran, J., Bawden, L. J., Figueiredo, R., Tawar, R., Wiseman, K., Henderson, E., Hoong, S.-J., Gonzalez, V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.152468 · Cited by 80 · see citing works
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
Archilla‐Ortega, A., Domuro, C., Martín-Liberal, J., & Muñoz, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02264-x · Cited by 79 · see citing works
Immune Checkpoint Receptors Signaling in T Cells
Baldanzi, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073529 · Cited by 71 · see citing works
Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy
Verdeil, G., Lawrence, T., Schmitt‐Verhulst, A., & Auphan‐Anezin, N. (2019) · Cancers · doi:10.3390/cancers11121832 · Cited by 63 · see citing works
Fan, Z., Tian, Y., Chen, Z., Liu, L., Zhou, Q., He, J., Coleman, J., Dong, C., Li, N., Huang, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911571 · Cited by 62 · see citing works
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
Borst, J. G., Busselaar, J., Bosma, D. M. T., & OSSENDORP, F. A. (2021) · European Journal of Immunology · doi:10.1002/eji.202048994 · Cited by 62 · see citing works
Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
Xu, X., Masubuchi, T., Cai, Q., Zhao, Y., & Hui, E. (2021) · eLife · doi:10.7554/elife.74276 · Cited by 59 · see citing works
Cis interactions between CD2 and its ligands on T cells are required for T cell activation
Li, B., Lü, Y., Zhong, M., Qian, J., Li, R., Davidson, D., Tang, Z.-H., Zhu, K., Argenty, J., de Peredo, A. G., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn6373 · Cited by 58 · see citing works
Self-citationSHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
Niogret, C., Birchmeier, W., & Guarda, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02468 · Cited by 48 · see citing works
Realigning the LIGHT signaling network to control dysregulated inflammation
Ware, C. F., Croft, M., & Neil, G. A. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220236 · Cited by 55 · see citing works
Immune cellular components and signaling pathways in the tumor microenvironment
Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 54 · see citing works
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells
Laba, S., Mallett, G., & Amarnath, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.022 · Cited by 51 · see citing works
Malissen, N., Macagno, N., Granjeaud, S., Granier, C., Moutardier, V., Gaudy‐Marqueste, C., Habel, N., Mandavit, M., Guillot, B., Pasero, C., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1665976 · Cited by 51 · see citing works
BTLA biology in cancer: from bench discoveries to clinical potentials
Andrzejczak, A., & Karabon, L. (2024) · Biomarker Research · doi:10.1186/s40364-024-00556-2 · Cited by 49 · see citing works
PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies
Nishimura, C., Pulanco, M. C., Cui, W., Lu, L., & Zang, X. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.10.004 · Cited by 46 · see citing works
Modulation of TCR Signaling by Tyrosine Phosphatases: From Autoimmunity to Immunotherapy
Castro-Sanchez, P., Teagle, A. R., Prade, S., & Zamoyska, R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.608747 · Cited by 44 · see citing works
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
Battin, C., Leitner, J. M., Waidhofer‐Söllner, P., Grabmeier‐Pfistershammer, K., Olive, D., & Steinberger, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956694 · Cited by 42 · see citing works
Wang, R., He, S., Long, J., Wang, Y., Jiang, X., Chen, M., & Wang, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00515-5 · Cited by 40 · see citing works
Wang, Q., Bardhan, K., Boussiotis, V. A., & Patsoukis, N. (2021) · Advanced Biology · doi:10.1002/adbi.202100758 · Cited by 39 · see citing works
Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway
Awadasseid, A., Wu, Y., & Zhang, W. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119813 · Cited by 39 · see citing works
Laletin, V., Bernard, P.-L., Silva, C. C. D., Guittard, G. C., & Nunès, J. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005845 · Cited by 40 · see citing works
Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer
Song, J., & Wu, L. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00148 · Cited by 38 · see citing works
Emergence of the CD226 Axis in Cancer Immunotherapy
Conner, M., Hance, K. W., Yadavilli, S., Smothers, J. F., & Waight, J. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914406 · Cited by 38 · see citing works
Mechanical forces amplify TCR mechanotransduction in T cell activation and function
Jeffreys, N. C., Brockman, J. M., Zhai, Y., Ingber, D. E., & Mooney, D. J. (2024) · Applied Physics Reviews · doi:10.1063/5.0166848 · Cited by 37 · see citing works
Self-citationFunctional differences between rodent and human PD-1 linked to evolutionary divergence
Masubuchi, T., Chen, L., Marcel, N., Wen, G. A., Caron, C., Zhang, J., Zhao, Y., Morris, G. P., Chen, X., Hedrick, S. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.ads6295 · Cited by 36 · see citing works
Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status
Schlicher, L., Green, L. G., Romagnani, A., & Renner, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1297175 · Cited by 34 · see citing works
Effects of PD-1 Signaling on Immunometabolic Reprogramming
Boussiotis, V. A., & Patsoukis, N. (2022) · Immunometabolism · doi:10.20900/immunometab20220007 · Cited by 33 · see citing works
Chen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 33 · see citing works
Paillon, N., Mouro, V., Dogniaux, S., Maurin, M., Sáez, J. J., Ferran, H., Bataille, L., Zucchetti, A. E., & Hivroz, C. (2023) · Science Signaling · doi:10.1126/scisignal.adh2456 · Cited by 32 · see citing works
Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?
Chen, X., Keller, S. J., Hafner, P., Alrawashdeh, A. Y., Avery, T. Y., Norona, J., Zhou, J., & Ruess, D. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340726 · Cited by 32 · see citing works
Gorgulho, J., Roderburg, C., Heymann, F., Schulze-Hagen, M. F., Beier, F., Vucur, M., Kather, J. N., Laleh, N. G., Tacke, F., Brümmendorf, T. H., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33610 · Cited by 32 · see citing works
Combination Approaches to Target PD-1 Signaling in Cancer
Moore, E. K., Strazza, M., & Mor, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927265 · Cited by 32 · see citing works
Ye, F., Cai, Z., Wang, B., Zeng, C., Xi, Y., Hu, S., Qu, R., Yuan, Z., Yue, J., Tian, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3009 · Cited by 30 · see citing works
Rapoport, B. L., Anderson, R., Cooksley, T., & Johnson, D. B. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05727-z · Cited by 27 · see citing works
Griffith, A. A., Callahan, K. P., King, N. G., Xiao, Q., Su, X., & Salomon, A. R. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00735 · Cited by 26 · see citing works
Xiang, S., Li, S., & Xu, J. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70345 · Cited by 26 · see citing works
SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function
Strazza, M., Adam, K. R., Lerrer, S., Straube, J., Sandigursky, S., Ueberheide, B. M., & Mor, A. (2021) · Inflammation · doi:10.1007/s10753-021-01437-8 · Cited by 23 · see citing works
Pan, M., Zhao, H., Jin, R., Leung, P. S. C., & Shuai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156212 · Cited by 23 · see citing works
Mechanisms, functions and therapeutic targeting of protein tyrosine phosphatases
Tiganis, T., & Tonks, N. K. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00882-9 · Cited by 22 · see citing works
Gleeson, F. C., Levy, M. J., Jackson, R. A., Murphy, S. J., Halling, K. C., Kipp, B. R., Graham, R. P., & Zhang, L. (2019) · Pancreatology · doi:10.1016/j.pan.2019.12.002 · Cited by 21 · see citing works
Patel, A., André, V., Eguiguren, S. B., Barton, M. I., Burton, J., Denham, E. M., Pettmann, J., Mørch, A. M., Kutuzov, M. A., Siller‐Farfán, J. A., et al. (2023) · The EMBO Journal · doi:10.1038/s44318-023-00012-1 · Cited by 21 · see citing works
Stienne, C., Virgen‐Slane, R., Elmeń, L., Veny, M., Huang, S. X. L., Nguyen, J., Chappell, E., Balmert, M. O., Shui, J., Hurchla, M. A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110553 · Cited by 20 · see citing works
Proteomics to study cancer immunity and improve treatment
Franciosa, G., Kverneland, A. H., Jensen, A. W. P., Donia, M., & Olsen, J. V. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-022-00980-2 · Cited by 20 · see citing works
TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways
Chan, W., Cao, Y. M., Zhao, X., Schrom, E. C., Jia, D., Song, J., Sibener, L. V., Dong, S., Fernandes, R. A., Bradfield, C. J., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20231242 · Cited by 20 · see citing works
The solute carrier superfamily interactome
Frommelt, F., Ladurner, R., Goldmann, U., Wolf, G., Inglés‐Prieto, Á., Liñeiro, E., Gelová, Z., Hopp, A.-K., Christodoulaki, E., Teoh, S. T., et al. (2025) · Molecular Systems Biology · doi:10.1038/s44320-025-00109-1 · Cited by 20 · see citing works
Determination of the molecular reach of the protein tyrosine phosphatase SHP-1
Clemens, L., Kutuzov, M. A., Bayer, K. V., Goyette, J., Allard, J. F., & Dushek, O. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.03.019 · Cited by 20 · see citing works
Gill, G. S., Kharb, S., Goyal, G., Das, P., Kurdia, K. C., Dhar, R., & Karmakar, S. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2504906 · Cited by 19 · see citing works
Hu, C., Huang, C., Wang, J., Hong, Y. M., Fan, D., Chen, Y., Lin, A., Xiang, L., & Shao, J.-Z. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300217 · Cited by 19 · see citing works
Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy
Awadasseid, A., Zhou, Y., Zhang, K., Tian, K., Wu, Y., & Zhang, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114057 · Cited by 18 · see citing works
Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response
Aquino, A., Bianchi, N., Terrazzan, A., & Franzese, O. (2023) · Biology · doi:10.3390/biology12081047 · Cited by 18 · see citing works
Consideration of SHP-1 as a Molecular Target for Tumor Therapy
Lim, S., Lee, K. W., Kim, J. Y., & Kim, K. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010331 · Cited by 18 · see citing works
The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA
Shen, C., Liu, J., Wang, J., Yang, X., Niu, H., & Wang, Y. (2020) · Disease Markers · doi:10.1155/2020/4312629 · Cited by 18 · see citing works
Targeting SHP1 and SHP2 to suppress tumors and enhance immunosurveillance
Zhao, Y., & Jiang, L. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.10.008 · Cited by 17 · see citing works
Mor, A., & Strazza, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.790386 · Cited by 16 · see citing works
Yang, C., Blaize, G., Marrocco, R., Rouquié, N., Bories, C., Gador, M., Mélique, S., Joulia, E., Benamar, M., Dejean, A. S., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abl5343 · Cited by 16 · see citing works
Chang, C., Pei, Y., Zhang, C., Zhang, W., Qin, Y., & Shi, S. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03525-0 · Cited by 15 · see citing works
Therapeutic implications for the PD-1 axis in cerebrovascular injury
Feghali, J., & Jackson, C. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00459 · Cited by 15 · see citing works
SAP interacts with CD28 to inhibit PD-1 signaling in T lymphocytes
Sandigursky, S., Philips, M. R., & Mor, A. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108485 · Cited by 15 · see citing works
Mélique, S., Yang, C., & Lesourne, R. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.03.008 · Cited by 13 · see citing works
Systems-level conservation of the proximal TCR signaling network of mice and humans
Nicolas, P., Ollier, J., Mori, D., Voisinne, G., Celis‐Gutierrez, J., Grégoire, C., Perroteau, J., Vivien, R., Camus, M., Burlet‐Schiltz, O., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211295 · Cited by 14 · see citing works
Self-citationConcomitant deletion of Ptpn6 and Ptpn11 in T cells fails to improve anticancer responses
Ventura, P., Gakovic, M., Fischer, B. A., Spinelli, L., Rota, G., Pathak, S., Khameneh, H. J., Zenobi, A., Thomson, S., Birchmeier, W., et al. (2022) · EMBO Reports · doi:10.15252/embr.202255399 · Cited by 14 · see citing works
Tumor Cell-Intrinsic BTLA Receptor Inhibits the Proliferation of Tumor Cells via ERK1/2
Cheng, T., Liu, Y., Yan, H., Xi, Y., Duan, L., Wang, Y., Zhang, T., Gu, Y., Wang, X., Wu, C., et al. (2022) · Cells · doi:10.3390/cells11244021 · Cited by 14 · see citing works
Yu, Y., Tang, H., Franceschi, D., Mujagond, P., Acharya, A., Deng, Y., Lethaus, B., Savković, V., Zimmerer, R. M., Ziebolz, D., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.759605 · Cited by 13 · see citing works
LAG ‐3—An incompletely understood target in cancer therapy
Leitner, J. M., Radakovics, K., & Steinberger, P. (2024) · The FASEB Journal · doi:10.1096/fj.202401639r · Cited by 12 · see citing works
Abramenko, N., Vellieux, F. M. D., Veselá, K., Kejík, Z., Hajduch, J., Masařík, M., Babula, P., Hoskovec, D., Pacák, K., Pavel Martasek, E., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51804-2 · Cited by 11 · see citing works
Mélique, S., Vadel, A., Rouquié, N., Yang, C., Bories, C., Cotineau, C., Saoudi, A., Fazilleau, N., & Lesourne, R. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318773121 · Cited by 11 · see citing works
Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event
Sanctis, J. B. D., Garmendia, J. V., Duchová, H., Valentini, V., Puskasu, A., Kubíčková, A., & Hajdúch, M. (2024) · Cancers · doi:10.3390/cancers16152630 · Cited by 11 · see citing works
Lam, W., Hu, R., Liu, S.-H., Cheng, P., & Cheng, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1095186 · Cited by 11 · see citing works
Chen, C., Cheng, Y., Lei, H., Feng, X., Zhang, H., Qi, L., Wan, J., Xu, H., Zhao, X. Y., Zhang, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115797 · Cited by 11 · see citing works
Zhao, R., Li, Z., Li, C., Xu, K., Zhen, L., Song, W., & Shi, J.-H. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.12.009 · Cited by 11 · see citing works
Zhang, Y., Yang, Y., Zeng, Y., Qu, Q., Shen, D. H., Mu, C., Lei, W., Su, M., Mao, J., Gao, L., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1553042 · Cited by 10 · see citing works
Foster, C., Du, J., Pundel, O. J., Geer, M. J., Ripert, R. C., Liu, J., Heim, T. A., Araki, K. Y., Lund, A. W., Wang, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2427254122 · Cited by 10 · see citing works
Role of BTLA/HVEM network in development of gastric cancer
Azarafza, M., Tehrani, M., Valadan, R., Maleki, I., Hamedani, S. M. M. G., Ghanadan, A., Alizadeh‐Navaei, R., & Ajami, A. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.07.003 · Cited by 10 · see citing works
Hou, B., Hu, Y., Zhu, Y., Wang, X., Li, W., Tang, J., Jia, X., Wang, J., Yu, C., Quan, M., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300462 · Cited by 10 · see citing works
Chyuan, I., Liao, H., Tan, T., Chuang, H., Chu, Y.-C., Pan, M.-H., Wu, C., Chu, C., Sheu, B., & Hsu, P. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01023-8 · Cited by 10 · see citing works
Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy
Peng, Y., Zhan, L., Shi, J., Wang, J., Li, Y., Sun, X., Lv, J., Yang, H., Qiu, Z., Liu, X., et al. (2025) · MedComm · doi:10.1002/mco2.70321 · Cited by 9 · see citing works
- Authors
- Celis-Gutierrez, J., Blattmann, P., Zhai, Y., Jarmuzynski, N., Ruminski, K., Grégoire, C., Ounoughene, Y., Fiore, F., Aebersold, R., Roncagalli, R., Gstaiger, M., & Malissen, B.
- Affiliations
- ETH Zurich (CH)
- Centre National de la Recherche Scientifique (FR)
- University of Zurich (CH)
- Corresponding author
- Roncagalli, Romain
- Gstaiger, Matthias
- Malissen, Bernard
- ORCID
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 27
- Issue
- 11
- Pages
- 3315-3330.e7
- ISSN
- 2211-1247 (ISSN-L)
- PMC
- PMC6581740
- OpenAlex
- W2951023546
- Cited by
- 154
- References
- 53
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 21 · 2023: 28 · 2022: 28 · 2021: 23 · 2020: 18 · 2019: 7
- FWCI
- 7.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cell Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
- HAL (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- ETH Zürich Research Collection (cc-by)
- Funders
- Agence Nationale de la Recherche
- European Research Council
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- PD-1, BTLA, co-inhibitory receptors, SHP-1, SHP2, protein tyrosine phosphatase, T cell signaling, T cell receptor signaling, CD28 signaling, T cell-antigen-presenting cell interaction, cancer immunotherapy, T cell exhaustion
- MeSH terms
- Animals, Female, Humans, Immunotherapy, Male, Mice, Inbred C57BL, Protein Binding, Receptors, Antigen, T-Cell, Receptors, Immunologic, T-Lymphocytes, Signal Transduction, Jurkat Cells, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
